Nexalin Technology reported positive results from an eight-week clinical trial of its 15 mA, 77.5 Hz neurostimulation protocol in adults with generalized anxiety disorder. The update is a favorable clinical milestone for the company’s non-invasive DIFS platform and supports its development narrative in mental health. The news is likely supportive for NXL shares but is still early-stage and limited to a single trial readout.
Nexalin Technology reported positive results from an eight-week clinical trial of its 15 mA, 77.5 Hz neurostimulation protocol in adults with generalized anxiety disorder. The update is a favorable clinical milestone for the company’s non-invasive DIFS platform and supports its development narrative in mental health. The news is likely supportive for NXL shares but is still early-stage and limited to a single trial readout.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
moderately positive
Sentiment Score
0.60
Ticker Sentiment
